HER2 Mutant Non-small Cell Lung Cancer
Oncology·MeSH: Carcinoma, Non-Small-Cell Lung
Prevalence
30.0 / 100K
1 drug in development·1 company·1 clinical trial
Drug Pipeline by Phase
Phase 1(1)
| Drug | Company |
|---|---|
| elvn-002 | Enliven Therapeutics, Inc. (ELVN) |
Frequently asked questions
How many drugs are in development for HER2 Mutant Non-small Cell Lung Cancer?
BioSniper tracks 1 drug in development for HER2 Mutant Non-small Cell Lung Cancer across 1 company.
How many clinical trials target HER2 Mutant Non-small Cell Lung Cancer?
There are 1 clinical trial targeting HER2 Mutant Non-small Cell Lung Cancer tracked by BioSniper.
What is the prevalence of HER2 Mutant Non-small Cell Lung Cancer?
The estimated prevalence of HER2 Mutant Non-small Cell Lung Cancer is approximately 30.0 per 100,000 population.
Deep-dive into HER2 Mutant Non-small Cell Lung Cancer
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis